Part 3: Use Safe Burial Practices
Statement
Impact of migration on infectious diseases in Europe | August 2007 | 1-7
J Epidemiol Infect Dis 1(1): 00003.n DOI: 10.15406/jeid.2017.01.00003
Published: September 14, 2017
In 2022, humanitarian action will need to adapt to new and challenging realities. The COVID-19 pandemic is taking a heavy toll in developing countries, civilians continue to be the most affected by conflict and extreme poverty is rising. Climate change effects are devastating, forced displacement is... at record levels and 161 million people face acute food insecurity.
more
Coronaviruses are a large family of viruses that are known to cause illness ranging from the common cold to more severe diseases such as Middle East Respiratory Syndrome (MERS) and Severe Acute Respiratory Syndrome (SARS).
A novel coronavirus (CoV) was identified in 2019 in Wuhan, China. This is a ...new coronavirus that has not been previously identified in humans.
This course provides a general introduction to nCoV and emerging respiratory viruses and is intended for public health professionals, incident managers and personnel working for the United Nations, international organizations and NGOs.
This course is also available in the following languages:
français - Español - 中文 - Português - العربية - русский - Türkçe - српски језик - فارسی - हिन्दी, हिंदी - македонски јазик - Tiếng Việt - Indian sign language - magyar - Bahasa Indonesia - বাংলা - اردو - Kiswahili - አማርኛ - ଓଡିଆ - Hausa - Tetun - Deutsch - Èdè Yorùbá - Asụsụ Igbo - ਪੰਜਾਬੀ - isiZulu
more
This document aims to support public health preparedness planning and response activities on the safe handling of bodies of deceased persons with suspected or confirmed COVID-19: at the site of death, during transport, storage and preparation before burial/cremation, and during burial/cremation.
Les retours d’information de la communauté présentés dans le présent rapport ont été recueillis par le biais des personnes chargées de l’engagement communautaire et de la redevabilité (CEA) dans 10pays africains, et grâce à la collecte de données primaires.Il a été demandé aux pers...onnes chargées du CEA de la Société nationale de la Croix-Rouge et du Croissant-Rouge de partager les principales rumeurs, observations, croyances, questions ou suggestions qu’ils entendent dans leur pays et de les classer par ordre de fréquence. Les chargés de mission du CEA ont fourni des informations de cette manière aux pays suivants: Afrique du Sud, Botswana, Burundi, Cameroun, Niger.
more
Centre de traitement des infections respiratoires aiguës sévères : manuel pratique pour la mise en place et la gestion d’un centre de traitement des IRAS et d’une unité de dépistage des IRAS dans les établissements de soins
IBOGA Review No.1 Revue Scientifique du Jésuites d'Afrique de l'Ouest
After 100 years of chemotherapy with impractical and toxic drugs, an oral cure for human African trypanosomiasis (HAT) is available: Fexinidazole. In this case, we review the history of drug discovery for HAT with special emphasis on the discovery, pre-clinical development, and operational challenge...s of the clinical trials of fexinidazole. The screening of the Drugs for Neglected Diseases initiative (DNDi) HAT-library by the Swiss TPH had singled out fexinidazole, originally developed by Hoechst (now Sanofi), as the most promising of a series of over 800 nitroimidazoles and related molecules. In cell culture, fexinidazole has an IC50 of around 1 µM against Trypanosoma brucei and is more than 100-fold less toxic to mammalian cells. In the mouse model, fexinidazole cures both the first, haemolymphatic, and the second, meningoencephalitic stage of the infection, the latter at 100 mg/kg twice daily for 5 days. In patients, the clinical trials managed by DNDi and supported by Swiss TPH mainly conducted in the Democratic Republic of the Congo demonstrated that oral fexinidazole is safe and effective for use against first- and early second-stage sleeping sickness. Based on the positive opinion issued by the European Medicines Agency in 2018, the WHO has released new interim guidelines for the treatment of HAT including fexinidazole as the new therapy for first-stage and non-severe second-stage sleeping sickness caused by Trypanosoma brucei gambiense (gHAT). This greatly facilitates the diagnosis and treatment algorithm for gHAT, increasing the attainable coverage and paving the way towards the envisaged goal of zero transmission by 2030.
more
Treatment of second-stage gambiense human African trypanosomiasis relied on toxicarsenic-based derivatives for over 50 years. The availability and subsequent use of eflornithine,initially in monotherapy and more recently in combination with nifurtimox (NECT), has drasticallyimproved the pro...gnosis of treated patients. However, NECT logistic and nursing requirementsremain obstacles to its deployment and use in peripheral health structures in rural sub-SaharanAfrica. Two oral compounds, fexinidazole and SCYX-7158, are currently in clinical development.The main scope of this article is to discuss the potential impact of new oral therapies to improvediagnosis-treatment algorithms and patients’access to treatment, and to contribute to reach theobjectives of the recently launched gambiense humanAfrican trypanosomiasis elimination program
more
Non- Communicable Diseases (NCDs) over the years have not been given much attention in Ghana and in most Low and Middle- Income Countries (LMICs). The overwhelming burden of communicable diseases and the scarcity of resources has led to the health of all residents in Ghana, NCDs still remain largely... underfunded and less prioritized. Attempts in the past have achieved little success. The formulation of Ghana´s NCD policy in 2014 and the accompanying strategic plan is one such effort.
more